Cargando…
Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer
INTRODUCTION: Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Antiviral therapy in patients with HCV infection reduces the risk of primary HCC development by 71%–75%. HCV-infected patients with different primary cancers are also at...
Autores principales: | Dandachi, Dima, Hassan, Manal, Kaseb, Ahmed, Angelidakis, Georgios, Torres, Harrys A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080868/ https://www.ncbi.nlm.nih.gov/pubmed/30123783 http://dx.doi.org/10.2147/JHC.S164568 |
Ejemplares similares
-
The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017) -
Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series
por: Torres, Harrys A, et al.
Publicado: (2014) -
2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
por: Angelidakis, Georgios, et al.
Publicado: (2018) -
2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
por: Hosry, Jeff, et al.
Publicado: (2018) -
Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies
por: Torres, Harrys A., et al.
Publicado: (2022)